Sanofi Highlights MS Asset After Solid Q4
BTK Inhibitor Entering Phase III Soon
Executive Summary
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.
You may also be interested in...
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone
Hudson finds solution for legacy sites which have dogged predecessors.
Incyte Ready To Go For Approval Of Topical Ruxolitinib In Atopic Dermatitis
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.